Novel therapeutics: NSAIDs, derivatives, and phosphodiesterases

Current Colorectal Cancer Reports

Volumn 8, Issue 4, 2012, Pages 325-330

  Tinsley, Heather N ^a   Piazza, Gary A ^b  

^a UNIVERSITY OF MONTEVALLO   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Colon cancer; Cyclic guanosine monophosphate; Nonsteroidal antiinflammatory drug; Phosphodiesterase; Sulindac

Indexed keywords

BENZYLAMINE DERIVATIVE; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; SULINDAC; SULINDAC SULFONE; TADALAFIL;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CHEMOPROPHYLAXIS; COLORECTAL CANCER; HUMAN; LONG TERM CARE; SIGNAL TRANSDUCTION;

EID: 84869133743     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-012-0142-5     Document Type: Article

References (69)

1. Earnest DL, Hixson LJ, Alberts DS. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl. 1992;16I:156-66.
2. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011;4(11):1728-35.
3. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets. 2004;4(1):29-42.
4. Turner D, Berkel HJ. Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. CMAJ. 1993;149(5):595-602.
5. Bastiaannet E, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564-70.
6. Bertagnolli MM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873-84.
7. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 2002;3(3):166-74.
8. Giardiello FM, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313-6.
9. Matsuhashi N, et al. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut. 1997;40(3):344-9.
10. Matsuhashi N, et al. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp. Am J Gastroenterol. 1998;93(11):2261-6.
11. Nugent KP, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80(12):1618-9.
12. Phillips RK, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50(6):857-60.
13. Steinbach G, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946- 52.
14. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-66.
15. Thun MJ, Namboodiri MM, Heath Jr. CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325(23):1593-6.
16. Williams CS, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000;60(21):6045-51.
17. Ruder EH, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106(7):1340-50.
18. Elder DJ, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997;3 (10):1679-83.
19. Grosch S, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J. 2001;15(14):2742-4.
20. Hanif R, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996;52(2):237-45.
21. Kusuhara H, et al. Induction of apoptotic DNA fragmentation by nonsteroidal anti-inflammatory drugs in cultured rat gastric mucosal cells. Eur J Pharmacol. 1998;360(2-3):273-80.
22. Piazza GA, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995;55 (14):3110-6.
23. Tinsley HN, et al. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila), 2010;3(10):1303-13. This article demonstrates the link between the anticancer activity of NSAIDs, including sulindac, and cGMP PDE inhibition.
24. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int J Tissue React. 1998;20(1):3-15.
25. Alberts DS, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl. 1995;22:18-23.
26. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
27. Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans. 2005;33(Pt 4):724-7.
28. Piazza GA, et al. Sulindac sulfone inhibits azoxymethaneinduced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997;57(14):2909-15.
29. Piazza GA, et al. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila Pa), 2009;2(6):572-80. This article presents the new approach to COX-independent NSAID design.
30. Piazza GA, et al. NSAIDs: Old drugs reveal new anticancer targets. Pharmaceuticals, 2010;3(5):1652-1667. This review discusses the proposed anticancer mechanisms of NSAIDs.
31. Piazza GA, et al. Apoptosis primarily accounts for the growthinhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57(12):2452-9.
32. Soh JW, et al. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog. 2008;47(7):519-25.
33. Thompson WJ, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60(13):3338-42.
34. Schmidt H. Cgmp: generators, effectors and therapeutic implications. New York, NY: Springer Heidelberg; 2008.
35. Feil R, Kemp-Harper B. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep. 2006;7(2):149-53.
36. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7(2):328-38.
37. Beavo J, Francis SH, and Houslay MD. Cyclic nucleotide phosphodiesterases in health and disease. Boca Raton: CRC; 2007. 713 p. 38 p. of plates.
38. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725-48.
39. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488-520.
40. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.
41. Sindic A, Schlatter E. Mechanisms of action of uroguanylin and guanylin and their role in salt handling. Nephrol Dial Transplant. 2006;21(11):3007-12.
42. Sindic A, Schlatter E. Cellular effects of guanylin and uroguanylin. J Am Soc Nephrol. 2006;17(3):607-16.
43. Birbe R, et al. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36(2):170-9.
44. Browning DD, Kwon IK, Wang R. cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med Chem. 2010;2(1):65-80.
45. Li P, Waldman SA. Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis. Cancer Biol Ther. 2010;10(3):211-8.
46. Pitari GM, et al. Interruption of homologous desensitization in cyclic guanosine 3′,5′-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 2005;65 (23):11129-35.
47. Pitari GM, et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci U S A. 2003;100(5):2695-9.
48. Camici M. Guanylin peptides and colorectal cancer (CRC). Biomed Pharmacother. 2008;62(2):70-6.
49. Steinbrecher KA, et al. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am J Pathol. 2002;161(6):2169-78.
50. Waldman SA, et al. Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro. Cancer Epidemiol Biomarkers Prev. 1998;7(6):505-14.
51. Kwon IK, et al. Expression of cyclic guanosine monophosphatedependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis. Cancer. 2008;112(7):1462-70.
52. Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004;64(11):3966-73.
53. Pitari GM, et al. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA. 2001;98(14):7846-51.
54. Shailubhai K, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000;60 (18):5151-7.
55. Soh JW, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000;6(10):4136-41.
56. Zhu B, et al. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005;94(2):336-50.
57. Li P, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007;133(2):599-607.
58. Kwon IK, et al. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene. 2010;29(23):3423-34.
59. Tinsley HN, et al. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-cateninmediated transcription in human breast tumor cells. Cancer Prev Res (Phila). 2011;4(8):1275-84.
60. Tinsley HN, et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther. 2009;8(12):3331-40.
61. Whitt JD, et al. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and beta-catenin transcriptional activity. Cancer Prev Res (Phila), 2012;5 (6):822-33. This article presents the new approach to COXindependent NSAID design.
62. Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118 (9):2338-66.
63. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res. 2004;16 Suppl 1:S11-4.
64. Abadi AH, et al. Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. Eur J Med Chem. 2010;45(4):1278-86.
65. Ahmed NS, et al. Design, synthesis and structure-activity relationship of functionalized tetrahydro-beta-carboline derivatives as novel PDE5 inhibitors. Arch Pharm (Weinheim). 2011;344 (3):149-57.
66. Mohamed HA, et al. Synthesis and molecular modeling of novel tetrahydro-beta-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. J Med Chem. 2011;54 (2):495-509.
67. Ahmed NS, et al. A novel access to arylated and heteroarylated betacarboline based PDE5 inhibitors. Med Chem. 2010;6(6):374-87.
68. Abadi AH, et al. Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. Eur J Med Chem. 2010;45(1):90-7.
69. Abadi AH, et al. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. Arzneimittelforschung. 2009;59(8):415-21.